On April 3, 2018, Rhelixa, Inc. closed the transaction. The transaction included participation from new investors SIOS Corporation (TSE:3744), UT Research Institute, Capital Medica Ventures Co., Ltd. and individual investor Masatoshi Honda. The company issued shares through the third party allotment.